The aim of the study was to evaluate the prognostic value of bio-ADM and IL-6 regarding AKI or critical illness in COVID-19 patients and to compare them with DPP3 and routinely measured markers, making it the first study to our knowledge that investigates the prognostic value of bio-ADM compared to IL-6 measured at hospital admission in COVID-19 patients. This evidence concerns the gene IL6 and COVID-19.